• LAST PRICE
    8.6700
  • TODAY'S CHANGE (%)
    Trending Up0.3200 (3.8323%)
  • Bid / Lots
    8.6800/ 3
  • Ask / Lots
    8.6900/ 2
  • Open / Previous Close
    8.4100 / 8.3500
  • Day Range
    Low 8.2100
    High 8.7050
  • 52 Week Range
    Low 6.5600
    High 13.0900
  • Volume
    143,506
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 8.35
TimeVolumeVIR
09:32 ET94808.42
09:33 ET75378.36
09:35 ET18248.21
09:37 ET2008.315
09:39 ET2208.2397
09:42 ET106078.33
09:44 ET9258.375
09:46 ET8998.38
09:48 ET22008.35
09:50 ET5008.38
09:51 ET1808.38
09:53 ET4448.41
09:55 ET18208.44
09:57 ET26098.41
10:00 ET4208.439
10:02 ET25218.475
10:04 ET13748.54
10:06 ET9418.58
10:08 ET43908.62
10:09 ET82178.655
10:11 ET37528.66
10:13 ET45908.63
10:15 ET57718.655
10:18 ET119198.61
10:20 ET52388.65
10:22 ET9508.64
10:24 ET139558.7
10:26 ET65958.67
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVIR
Vir Biotechnology Inc
1.1B
-2.2x
---
United StatesZYME
Zymeworks Inc
981.5M
-9.2x
---
United StatesGYRE
Gyre Therapeutics Inc
1.1B
-50.4x
---
United StatesIMTX
Immatics NV
936.9M
-12.4x
---
United StatesPSTX
Poseida Therapeutics Inc
912.3M
-14.8x
---
United StatesNRIX
Nurix Therapeutics Inc
1.5B
-7.1x
---
As of 2024-12-09

Company Information

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

Contact Information

Headquarters
1800 OWENS STREET, SUITE 900SAN FRANCISCO, CA, United States 94158
Phone
415-906-4324
Fax
302-636-5454

Executives

Independent Chairman of the Board
Vicki Sato
Chief Executive Officer, Director
Marianne De Backer
Chief Financial Officer, Executive Vice President
Jason O'byrne
Executive Vice President, Chief Technology Officer
Ann Hanly
Executive Vice President, Chief Scientific Officer
Jennifer Towne

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.1B
Revenue (TTM)
$78.6M
Shares Outstanding
137.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.49
EPS
$-3.92
Book Value
$11.80
P/E Ratio
-2.2x
Price/Sales (TTM)
14.6
Price/Cash Flow (TTM)
---
Operating Margin
-774.67%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.